Key Segmentation:
By Type
-
Diagnostic Radiopharmaceuticals
-
Therapeutic Radiopharmaceuticals
By Isotope
-
Technetium-99m
-
Fluorine-18
-
Gallium-68
-
Lutetium-177
-
Iodine-131
-
Other Isotopes
By Application
-
Oncology
-
Cardiology
-
Neurology
-
Other Applications
By End User
-
Hospitals and Clinics
-
Diagnostic Imaging Centers
-
Academic and Research Institutes
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Novartis (Advanced Accelerator Applications), Lantheus, Curium, Telix, GE HealthCare, Cardinal Health, Jubilant Radiopharma, Eckert & Ziegler, ITM, Orano Med and NorthStar Medical Radioisotopes.
Key opportunities include alpha emitter therapies, new targets beyond prostate cancer, domestic isotope production and growth in emerging markets.
Rising cancer incidence and the spread of theranostics, supported by new approvals and a deep clinical pipeline, are the main growth factors.
By Type, the Diagnostic Radiopharmaceuticals segment dominated the market in 2025 with an estimated 68.48% share, supported by high PET and SPECT scan volumes.
North America dominated the market with a share of 44.41% in 2025, driven by early approvals, large cancer centers and strong reimbursement.